Thermo Fisher Scientific Inc. - 10-Q Summary (Q3 2008)
Business Context and Reporting Period
This filing covers the quarterly report for Thermo Fisher Scientific Inc. for the three and nine months ended September 27, 2008. The company operates in two primary segments: Analytical Technologies and Laboratory Products and Services. The company develops, manufactures, and sells a broad range of products for life sciences, environmental, and healthcare markets globally.
Key Financial Metrics
| Metric (in millions) | Q3 2008 | Q3 2007 | 9M 2008 | 9M 2007 |
|---|---|---|---|---|
| Revenues | $2,588.1 | $2,401.2 | $7,851.7 | $7,125.3 |
| Operating Income | $286.3 | $254.0 | $906.9 | $689.4 |
| Net Income | $221.5 | $218.5 | $704.0 | $521.3 |
| Diluted EPS | $0.51 | $0.49 | $1.61 | $1.17 |
| Operating Margin | 11.1% | 10.6% | 11.6% | 9.7% |
| Cash from Operations (9M) | $960.0 | $948.2 | ||
| Cash & Equivalents (End of Period) | $1,240.3 | |||
| Total Debt (Outstanding) | $2,181.8 |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2008 revenues increased 8% year-over-year, driven by a $39 million favorable currency impact, $65 million from acquisitions, and $83 million from organic growth (higher demand and price increases). Nine-month revenue growth was 10%.
- Profitability: Operating income increased 13% in Q3 and 32% for the nine-month period. Margins expanded due to productivity improvements, global sourcing, and lower restructuring costs compared to the prior year, partially offset by higher amortization of acquisition-related intangibles and commodity inflation.
- Restructuring: Net restructuring costs were $15.4 million in Q3 2008 (up from $8.8 million in Q3 2007) but $14.9 million for the nine months (down from $24.5 million in 2007). The nine-month decrease was primarily due to an $18.5 million gain from the curtailment of a U.S. pension plan.
- Tax Rate: The effective tax rate increased to 17.4% in Q3 2008 from 7.1% in Q3 2007. The prior year rate was artificially low due to a one-time $21 million benefit from tax rate reductions in the UK, Denmark, and Germany.
Guidance, Outlook, and Risks
- Outlook: Management expects the full-year 2008 effective tax rate to be approximately 17%-18%. Capital expenditures for the full year are expected to approximate $210-$225 million.
- Restructuring: The company expects to record an additional $12 million in severance charges in Q4 2008 related to cost reduction measures, expected to yield $26 million in annual cost savings.
- Liquidity: The company holds $1.25 billion in cash and short-term investments. It maintains a $954 million revolving credit facility. Management believes these resources are sufficient for the next 24 months.
- Convertible Debt Risk: Approximately $974 million of outstanding debt is convertible. Holders of $344 million in Floating Rate Senior Convertible Debentures have the right to put the debentures to the company in December 2008. The company plans to use its credit facility to fund any such payments.
- Accounting Changes: Adoption of FSP APB No. 14-1 in 2009 is expected to increase annual interest expense by approximately $23 million, reducing EPS by roughly $0.03.
- Risks: Key risks include the global credit crisis and potential recession impacting customer spending, intellectual property litigation (specifically a patent infringement suit regarding mass spectrometers), and exposure to currency fluctuations.
Investor Verification Checklist
- Convertible Debt Put Option: Verify the likelihood of the $344 million put option exercise in December 2008 and the company's liquidity plan to fund it.
- Q4 Restructuring Charges: Confirm the timing and impact of the anticipated $12 million Q4 restructuring charge on year-end earnings.
- 2009 Interest Expense Impact: Assess the impact of the new accounting rule (FSP APB No. 14-1) on 2009 interest expense and EPS.
- Customer Concentration: Review the impact of the revised agreement with a major healthcare market customer, which is expected to reduce annualized revenues by approximately $75 million starting in 2009.
- Goodwill Valuation: Monitor the $8.75 billion goodwill balance for potential impairment risks given the uncertain economic climate.